SMAD3 and breast cancer: For example, in the metastatic breast cancer cell model MDA-MB-231, Smad2 knock-down led to a more aggressive phenotype, while Smad3 knock-down led to a lag in tumor initiation, suggesting that Smad2 and Smad3 have opposing effects on disease progression [14].